Compass Therapeutics to Commence Trading on the OTCQB Venture Market Under the Symbol “CMPX”
March 04 2021 - 4:59PM
Business Wire
Compass Therapeutics, Inc. (OTCQB: CMPX), a clinical-stage
biotechnology company developing proprietary antibody therapeutics
intended to engage the immune system to treat both solid tumors and
hematological malignancies, announced today that shares of the
company’s common stock have been cleared for trading on the OTCQB
Venture Market in the United States. The Company’s shares will
trade under the ticker symbol "CMPX", effective at the market open
on March 5, 2021.
About Compass Therapeutics
Compass Therapeutics is a clinical-stage biopharmaceutical
company developing proprietary antibody therapeutics intended to
engage the immune system to treat both solid tumors and hematologic
malignancies. Compass is leveraging its proprietary StitchMabs™ and
common light-chain based multispecific platforms to empirically
identify multispecifics and combinations of antibody therapeutics
that synergistically modulate key nodes in the immune system. The
company’s lead product candidate, CTX-471, is a fully human
agonistic antibody of CD137, and is currently being evaluated in a
Phase 1 study in patients who were previously treated with
PD-1/PD-L1 checkpoint inhibitors and who subsequently relapsed or
progressed after a period of stable disease. The company’s offices
and labs are located in Boston, MA. Its website is at
www.compasstherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements.
Statements in this press release that are not purely historical are
forward-looking statements. Such forward-looking statements
include, among other things, the commencement of trading on OTCQB,
references to our product candidates and the development and
therapeutic potential thereof, our technologies for identifying
additional product candidates, and our business and development
plans. Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, our ability to raise the additional funding
we will need to continue to pursue our business and product
development plans, the inherent uncertainties associated with
developing product candidates and operating as a development stage
company, our ability to identify additional product candidates for
development, our ability to develop, complete clinical trials for,
obtain approvals for and commercialize any of our product
candidates, and competition in the industry in which we operate and
market conditions. These forward-looking statements are made as of
the date of this press release, and Compass assumes no obligation
to update the forward-looking statements, or to update the reasons
why actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents we file with the SEC available at www.sec.gov,
including without limitation our Form 10-Q for the quarter ended
September 30, 2020, and our subsequent filings with the SEC.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210304006114/en/
Investor Contact Compass Therapeutics, Inc. Vered
Bisker-Leib, President & Chief Operating Officer
ir@compasstherapeutics.com Media Contact
media@compasstherapeutics.com 617-500-8099
Compass Therapeutics (NASDAQ:CMPX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Compass Therapeutics (NASDAQ:CMPX)
Historical Stock Chart
From Sep 2023 to Sep 2024